Article
The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
Atherosclerosis - 1 Jun 2015
Stefanutti C, Blom D J, Averna M R, Meagher E A, Theron H dT, Marais A D, Hegele R A, Sirtori C R, Shah P K, Gaudet D, Vigna G B, Sachais B S, Di Giacomo S, du Plessis A M E, Bloedon L T, Balser J, Rader D J, Cuchel M
Abstract excerpt
OBJECTIVE: Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.